E2/LNG oral (Wellnara, BAY86-5029)

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopause

Conditions

Postmenopause

Trial Timeline

Sep 1, 2007 โ†’ May 1, 2009

About E2/LNG oral (Wellnara, BAY86-5029)

E2/LNG oral (Wellnara, BAY86-5029) is a pre-clinical stage product being developed by Bayer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00913926. Target conditions include Postmenopause.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT01401114Pre-clinicalCompleted
NCT00913926Pre-clinicalCompleted